GLP-1 Market
LLY $1270.75 ▼ -1.0% NVO $39.27 ▼ -0.2% PFE $29.72 ▼ -1.3% VKTX $26.64 ▼ -0.3% KLRA $13.16 ▲ +2.1% GPCR $22.41 ▼ -2.1% RHHBY $59.12 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

BGE-102

BGE-102

Company
BioAge Labs, Inc.
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for BGE-102 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07812090

    A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

    Not yet reported BioAge Labs, Inc. 180 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Diabetic Macular Edema (DME)
    View official trial listing →
  • Active, not recruiting NCT NCT07656727

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Not yet reported BioAge Labs, Inc. 160 participants Est. completion 2026-12 17 sites Stand-alone
    Other conditions: Obesity and Cardiovascular Risk
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: BGE-102, Oral BGE-102

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.